TMO Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to generate, or has sentiment moved ahead of the underlying economics? The stock has returned 47.4% over the past year, which puts real pressure on the question of whether the current valuation still lines up with the cash being produced and...

On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel enables […]

Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...

Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as […]

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Dodge & Cox Fund, an investment management company, released its second-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. You can download a copy of the letter here. U.S. equities achieved new all-time highs in Q2 2026, driven by a rally in the technology sector, led by memory semiconductor stocks. In Q2 2026, the […]

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.

Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day share price return of 5.81%, building on a strong 90-day share price return of 31.55% as launches like the Gibco CHO-K1 Catalog Panel feed into a broader pipeline story. Over a longer horizon, the 1-year...

Thermo Fisher Scientific (NYSE:TMO) has introduced the Gibco CHO-K1 Catalog Panel, a new off the shelf media offering for biologics developers. The panel includes cGMP ready, chemically defined, animal origin free basal and feed media aimed at broad process development and manufacturing use. The new solution is designed to give biologics and biosimilars producers scalable, ready to use options for cell culture performance, productivity, and product quality. The launch of the Gibco CHO-K1...

Alex Bradley told CFO.com how AI is changing the software purchasing process and pulling many finance chiefs further into the buying process.

Thermo Fisher’s 36.4% return over the past six months has outpaced the S&P 500 by 20.1%, and its stock price has climbed to $652.30 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Market uncertainty persists, but Zacks highlights strong gains across key portfolios and stocks, including PBF, PLTR and ADBE

The company will generate population-scale molecular data to inform development of diagnostics, therapies and other healthcare products.

Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of […]

Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time highs, though the energy sector declined. Continued earnings growth, especially among […]

Key Stats for Thermo Fisher StockCurrent Price: $641. 39Target Price (Mid): ~$839Street Target: ~$645Potential Total Return: ~31%Annualized IRR: ~7% / yearWhat Happened?Thermo Fisher Scientific (TMO) has become the rare large-cap where three analysts studying the same company cannot agree on direction.

Thermo Fisher Scientific (NYSE:TMO) and Mayo Clinic announced the formation of Precure, LLC for early disease detection using multi omic data. Precure plans to integrate proteomic, genomic, and longitudinal clinical records into a single biomedical dataset to identify early disease signals. The collaboration positions Thermo Fisher Scientific’s technology at the center of large scale healthcare data generation for research and clinical decision support. The Precure, LLC launch is important,...

Thermo Fisher Scientific (NYSE:TMO) Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution. Speaking at Morgan Stanley’s G

Cisco, Lam Research and Thermo Fisher highlight AI, networking and life-science demand, while microcaps Ampco-Pittsburgh and Catalyst Bancorp offer added depth.

Cisco, Lam Research and Thermo Fisher headline today's research reports, with AI demand, customer activity and growth strategies in focus.

In an interview with CNBC on Tuesday, Marc Casper said AI is helping drugmakers identify ineffective medicines quicker while also shortening the time to market for promising therapies.

Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Stocks took a beating Tuesday as surging oil prices and looming inflation data rattled every corner of the market, and now Wall Street analysts are reshuffling their calls on names ranging from nuclear energy upstart Oklo to retail giants Abercrombie and Ulta Beauty.

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

Clark Howard named a specific age when corporate America tends to push workers out, and it falls years before most people's retirement plans even begin to account for income gaps, portfolio shortfalls, or Social Security decisions.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.

Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.

Despite a challenging market, the company realized over 14% of NAV in distributions and advanced AI initiatives, while navigating a dip in portfolio performance.

Thermo Fisher Scientific (NYSE:TMO) introduces the EMPAD G2 detector for high speed, high dynamic range 4D scanning transmission electron microscopy. The company launches Orbitrap Isora and Isora Pro Mass Spectrometers that integrate molecular level isotope ratio analysis. The new instruments target research in material science, environmental studies, geoscience, bioscience, and food authenticity. Consider looking at other stocks developing tools and infrastructure that support advanced...

Thermo Fisher Scientific has outperformed the Nasdaq over the past year, yet Wall Street analysts remain bullish on the stock, reflecting confidence that its strong growth trajectory has further room to run.

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Its growth profile stands well above major sector peers.

AVTR's Revival Program is lifting VWR growth and BMP orders, but margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook.

Amgen, Thermo Fisher and PepsiCo headline today's research, with growth drivers, strategic moves and key risks in focus.

SpaceX, trading at 93 times next year’s estimated earnings, seems hardly the stock to unite both short-term-focused hedge-fund managers and more long-term-oriented mutual-fund managers.

Turnarounds in the healthcare sector do not all look the same. Some companies recover because management executes better, launches stronger products, and improves operations, while others do so because the industries they serve begin improving after prolonged downturns. Medtronic (NYSE:MDT) and Thermo Fisher Scientific (NYSE:TMO) are two of healthcare’s most closely watched recovery stories, but […]

Healthcare investors are often faced with a choice between companies that generate steady growth across diversified businesses and those positioned to benefit from improving industry conditions. Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) represent those two approaches. Abbott (NYSE:ABT) continues to deliver broad-based growth across diagnostics, medical devices, and nutrition, while Thermo Fisher (NYSE:TMO) […]

Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher’s (NYSE:TMO) […]

Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher’s (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) continues to hold a dominant position in robotic surgery through factors such as its highly recurring revenue model. Both companies […]

Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. See our latest analysis for Thermo Fisher Scientific. The proteomics update arrives after a strong run in Thermo Fisher Scientific’s stock, with the share price at US$629.27 and a 30 day share price return of 19.53%, alongside a 1 year total shareholder return of 26.32% that...